Ga68-labeled Fibroblast Activation Protein Inhibitor-46 (Ga68-FAPI-46) PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This is a prospective, phase II, non-randomized clinical imaging trial. Ga68-FAPI-46 is a novel radiotracer used in PET/CT imaging, targeting a protein of the tumor microenvironment called FAP (Fibroblast activation protein). The aim of the study is to assess the accuracy of Ga68-FAPI-46 PET/CT for preoperative assessment of peritoneal carcinomatosis in colorectal and ovarian cancer.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Histologically proven colorectal and ovarian cancer.

• Known or suspected peritoneal metastases from the tumour of origin.

• Scheduled for peritoneal complete cytoreductive surgery with curative intent with or without neoadjuvant chemotherapy.

• ECOG (Eastern Cooperative Oncology Group) Performance status ≤2.

• Signed written informed consent obtained before any study-specific screening procedures.

Locations
Other Locations
Belgium
Institut Jules Bordet
RECRUITING
Brussels
Contact Information
Primary
Loubna Taraji Schiltz
loubna.taraji@hubruxelles.be
+32 (0) 2 541 37 81
Time Frame
Start Date: 2023-05-30
Estimated Completion Date: 2025-12
Participants
Target number of participants: 80
Treatments
Experimental: FAPI PET/CT
Patients with known or suspected peritoneal metastases from colorectal and ovarian cancers scheduled for complete cytoreductive surgery undergo FAPI PET/CT before the planned surgery.~In the target population, patients receiving neoadjuvant chemotherapy undergo FAPI PET/CT both before and after chemotherapy.
Related Therapeutic Areas
Ovarian Cancer
Sponsors
Leads: Jules Bordet Institute

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

[68Ga]Ga-FAPI-46 PET/CT: the Diagnostic Accuracy for Primary Staging and Re-staging of Patients with Ovarian Cancer

[68Ga]Ga-FAPI-46 PET/CT: the Diagnostic Accuracy for Primary Staging and Re-staging of Patients with Ovarian Cancer

Enrollment Status: Recruiting
Publish Date: January 30, 2025
Intervention Type: Drug
Study Phase: Phase 2

Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer With CA125 Elevation From Complete Response After Therapy

Evaluation of 68Ga-FAPI-46 and 18F-FDG PET/CT Imaging for Detecting Recurrent Tumor Lesions in Patients of Ovarian Cancer With CA125 Elevation From Complete Response After Therapy

Enrollment Status: Recruiting
Publish Date: January 30, 2024
Intervention Type: Diagnostic test
Study Phase: Not Applicable

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Enrollment Status: Recruiting
Publish Date: November 12, 2025
Intervention Type: Drug
Study Phase: Phase 2
View All